US Stock Market Closed

Dashboard

Alnylam Pharmaceuticals, Inc. (ALNY)

Current

- (-)

After Hours

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

B

Industry Comparison

B

Management & Equity

S

Analyst Opinion

S

Leverage & Liquidity

S

Fundamental Variables

H

Rating Performance

FV Performance

*There is a current rating on the stock that is included in these numbers based on its performance so far

About

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

CEO

John M. Maraganore

Employees

1,323

Industry

Endocrinology and Metabolism Biopharmaceuticals

Sector

Healthcare

Headquarters

Cambridge

Exchange

NASDAQ

Summary Stats

Market Cap

28.8B

Revenue

961M

Net Income

-1.18B

EPS

-$9.78

Price-to-Earnings

-23.97

Price-to-Book

-426.36

Debt-to-Equity

-53.27

News

Analyst Ratings

Price targets projected by 23 analysts

High

$225.00

Average

$163.61

Low

$93.00

Ratings calculated by 24 analysts

Buy

16

Hold

8

Sell

0

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q3 2022

Last Earnings

Above by $0.20

Actual

-$1.58 +11.2%

Consensus

-1.78

Report Date

Year Ago

-1.51

Year Ago Change %

Down 4%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites